Studies heart failure patients in Singapore who receive cardiac resynchronization therapy
Follows adults with heart failure who receive a resynchronization device over time.
Key facts
- Who runs it
- National University Heart Centre, Singapore
- Where
- Singapore, SingaporeSee the site
- Trial code
- Registry title
- Prospective Evaluation of Asians With CRT for Heart Failure
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- Jan 2011
- Expected to end
- Dec 2030
- Type of study
- Observational
- Treatments tested
- Cardiac Resynchronization Therapy
- Record updated
- 9 March 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with symptomatic heart failure who have a wide QRS on ECG and a low ejection fraction, and who are having cardiac resynchronization therapy (CRT).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Symptomatic heart failure with a broad QRS (more than 120 ms) and an ejection fraction (EF) below 40%
- Earlier treatment
- Not on optimal medical therapy
Main reasons for not taking part
- Pregnant
- Younger than 18 years
- Infection
- Unable to give consent
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Broad QRS (>120 ms)
- EF < 40%
- Symptomatic heart failure
- Not on optimal medical therapy
Who cannot take part
- Infection
- < 18 years of age
- Pregnant
- Unable to consent
Where in Singapore
- National University HospitalSingapore, SingaporeContact: Pipin Kojodjojo, MD PHDTaking people
About the trial
What the trial wants to find out
Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT.
Read full original descriptionShow less
Methodology:Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure.
The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.
The group in the trial
- Heart Failure receiving CRT
Heart failure patients with QRS \> 120ms receiving CRT
Treatment: Cardiac Resynchronization Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Evaluation of Asians With CRT for Heart Failure
- Plain-language title
- Studies heart failure patients in Singapore who receive cardiac resynchronization therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 March 2021